在未破裂的脊髓底剖析动脉瘤中,他类药物减少了血管壁MRI的壁增强:一项随机对照试验
Yisen Zhang1,2, Chao Wang1,2, Linggen Dong1,2
1Department of Neurosurgery and Department of Interventional Neuroradiology, Beijing Tiantan Hospital and Beijing Neurosurgical Institute, Capital Medical University, NansihuanXilu 119, Fengtai District, Beijing, China 100070.
Radiology
|December 23, 2025
概括
正如血管壁MRI所示,阿托瓦斯塔丁显著降低了脊髓基底剖析动脉瘤 (VBDA) 的炎症. 这项研究表明,他类药物可能是减少VBDA炎症和中风风险的潜在治疗方法.
科学领域:
- 神经学 神经学
- 放射学 放射学是指放射学
- 心血管研究研究心血管研究
背景情况:
- 脊髓底剖析动脉瘤 (VBDA) 是中风的重要原因之一.
- 血管壁上的动脉瘤壁增强 (VW) MRI表明炎症.
- 对于他类药物对VBDA炎症的影响尚不清楚.
研究的目的:
- 为了研究6个月的阿托瓦斯塔丁治疗对使用VWMRI的VBDA壁增强的影响.
- 评估动脉瘤大小,形态和炎症生物标志物的变化.
主要方法:
- 一个开放的,随机的受控试验,涉及未破裂的VBDAs的参与者.
- 参与者被随机分配,每天接受20毫克阿托瓦斯塔丁或对照剂.
- 在基线和6个月的随访期间进行了VW MRI,以测量墙壁增强指数 (WEI) 和墙壁增强体积率 (WEVR).
主要成果:
- 与对照组相比,阿托瓦斯塔丁治疗导致WEI和WEVR显著下降.
- 炎症生物标志物,包括C反应蛋白和细胞因子,在阿托瓦斯塔丁组有所改善.
- 在阿托瓦斯塔丁组中,内血瘤的进展减缓了.
结论:
- 阿托瓦斯塔丁有效地降低了VWMRI上的VBDA壁增强.
- 这些发现表明阿托瓦斯塔丁可能有助于控制VBDAs中的炎症.
- 需要进一步的研究来探索他类药物作为VBDAs的治疗选择.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291


